Skip to content
Evigrade
MajorNon-steroidal anti-inflammatory drugs (NSAIDs)×Direct oral anticoagulants (factor Xa inhibitors)

Updated · Methodology

Mechanism

Edoxaban blocks clotting factor Xa (edoxaban SmPC, EMA). Diclofenac, like other non-steroidal anti-inflammatory drugs (NSAIDs), can temporarily inhibit platelet aggregation and cause ulcers and bleeding in the stomach and gut (diclofenac summary of product characteristics, SmPC). According to clinical studies, diclofenac does not seem to change the action of anticoagulants. There are, however, reports of more frequent bleeding when the two are combined (diclofenac SmPC). In clinical studies, NSAIDs given with edoxaban increased clinically relevant bleeding (edoxaban SmPC, European Medicines Agency, EMA). Among NSAIDs, pharmacokinetic data with edoxaban exist only for naproxen, which did not change edoxaban levels (edoxaban SmPC, EMA).

Symptoms

The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can occur at any site and can be severe (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Diclofenac adds a risk of ulcers and gastrointestinal bleeding, especially in older people, in people with a previous ulcer and at higher doses (diclofenac SmPC). Such bleeding presents as black, tarry stools (melaena), vomiting of blood or coffee-ground material, and abdominal pain. An unexplained fall in haemoglobin or blood pressure can point to hidden bleeding (edoxaban SmPC, EMA).

Management

The edoxaban summary of product characteristics (SmPC) does not recommend long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) with edoxaban (edoxaban SmPC, European Medicines Agency, EMA). Give diclofenac at the lowest effective dose for the shortest time. Use it with caution together with anticoagulants and monitor the patient closely (diclofenac SmPC). If long-term NSAID treatment cannot be avoided, monitor carefully for bleeding and promptly evaluate any sign of blood loss (edoxaban prescribing information, US Food and Drug Administration, FDA). Diclofenac is contraindicated in established congestive heart failure (New York Heart Association, NYHA, class II–IV), ischaemic heart disease, peripheral arterial disease and cerebrovascular disease (diclofenac SmPC). In older patients and in those with a previous ulcer, start diclofenac at the lowest effective dose and give it with gastroprotection (misoprostol or a proton pump inhibitor). Consider the same protection when other drugs raise the risk of gastrointestinal bleeding (diclofenac SmPC). Check creatinine clearance before starting edoxaban and later when clinically indicated (edoxaban SmPC, EMA). Diclofenac is contraindicated in severe renal impairment. In mild to moderate impairment, use it with caution (diclofenac SmPC). Edoxaban is contraindicated in a lesion or condition that carries a significant risk of major bleeding, such as an active or recent gastrointestinal ulcer (edoxaban SmPC, EMA). Diclofenac is contraindicated in active ulcer, bleeding or perforation and after previous NSAID-related bleeding or perforation (diclofenac SmPC). Stop diclofenac at once if gastrointestinal bleeding or an ulcer occurs (diclofenac SmPC). In severe bleeding, interrupt edoxaban as well (edoxaban SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Diclofenac

Other interactions with Edoxaban